Y-mAbs was founded in April 2015 by Thomas Gad, father of a neuroblastoma cancer survivor. Today, Mr. Gad is Chairman of the Board of Directors, and President and Head of Business Development and Strategy.
Y-mAbs is a late-stage clinical, global biopharmaceutical company focused on developing antibody therapeutics for oncology targets, based on a range of technologies licensed from Memorial Sloan Kettering Cancer Center under an exclusive worldwide license and research collaboration agreement.
Y-mAbs applies its world-class antibody capabilities to various immunotherapies for cancer patients of all ages. Y-mAbs’ product candidates have evolved through extensive drug development capabilities.
Y-mAbs offers truly unique and exciting career opportunities in a young and growing international company that fosters an open and trusting atmosphere. Y-mAbs provides significant professional and personal growth opportunities for its employees.
We are committed to helping employees maintain a balance between work life and personal time by providing paid vacation, public holidays, and other benefits such as disability and health benefits. Benefits are managed locally, to comply with local legislation.
Our mission is to become the world leader in developing investigational antibody-based cancer products that address clear unmet needs in pediatric and adult oncology.
Our commitment to bringing new therapeutics to the market with the goal of improving patients’ lives is a strong motivator for all of the employees at Y-mAbs.
Our goal is to foster a culture of excellence in execution, where employees are focused on clear priorities and are passionate about advancing our vision. We work cross-functionally and internationally as one team to gain the most from all competencies.
Our employees work with determination and with respect for each other to achieve our tasks and common goals. We give individuals and teams the autonomy to drive development of innovative products and solutions, knowing that integrity is a core value throughout our company.